Skip to main content
logo
Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London flag London · Delayed Price · Currency is GBP · Price in USD
451.70
+1.69 (0.38%)
At close: Oct 3, 2025

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 20212013 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 2013 - 2020
AMVUTTRA Revenue
1.35B970.45M
Log In
Log In
Log In
Upgrade
ONPATTRO Revenue
208.42M252.86M
Log In
Log In
Log In
Upgrade
GIVLAARI Revenue
283.51M255.87M
Log In
Log In
Log In
Upgrade
OXLUMO Revenue
172.75M167.05M
Log In
Log In
Log In
Upgrade
Total Product Revenue
2.01B1.65B
Log In
Log In
Log In
Upgrade
Roche - Collaboration Revenue
63.63M119.49M
Log In
Log In
Log In
Upgrade
Regeneron Pharmaceuticals - Collaboration Revenue
152.19M302.80M
Log In
Log In
Log In
Upgrade
Novartis AG - Collaboration Revenue
-79.76M
Log In
Log In
Log In
Upgrade
Vir Biotechnology - Collaboration Revenue
--
Log In
Log In
Log In
Upgrade
Other - Collaboration Revenue (Pre-FY2023)
--
Log In
Log In
Log In
Upgrade
Other - Collaboration Revenue (Post-FY2022)
46.27M8.18M
Log In
Log In
Log In
Upgrade
Total Collaboration Revenue
325.02M510.22M
Log In
Log In
Log In
Upgrade
Royalty Revenue
125.22M91.79M
Log In
Log In
Log In
Upgrade
Revenue (Other)
-262.08M-510.22M
Log In
Log In
Log In
Upgrade
Revenue (Total)
2.46B2.25B
Log In
Log In
Log In
Upgrade
Updated Jun 30, 2025. Data Source: Fiscal.ai.